ALGS
Aligos Therapeutics Inc
$
10.550
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.1925
Open
11.060
VWAP
10.67
Vol
61.19K
Mkt Cap
64.90M
Low
10.0701
Amount
652.91K
EV/EBITDA(TTM)
--
Total Shares
78.11M
EV
-54.75M
EV/OCF(TTM)
--
P/S(TTM)
27.54
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
333.33K
+7.18%
-2.067
-140.36%
500.00K
-20.51%
-1.992
-84.79%
500.00K
-60.6%
-1.900
-38.11%
Estimates Revision
The market is revising No Change the revenue expectations for Aligos Therapeutics, Inc. (ALGS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 83.96%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-17.39%
In Past 3 Month
Stock Price
Go Up
+83.96%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast ALGS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALGS is 50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 10.550
Low
50.00
Averages
50.00
High
50.00
Current: 10.550
Low
50.00
Averages
50.00
High
50.00
H.C. Wainwright
initiated
$50
2025-08-18
Reason
H.C. Wainwright
Price Target
$50
2025-08-18
initiated
Reason
H.C. Wainwright assumed coverage of Aligos Therapeutics with a Buy rating and $50 price target. The firm has conviction that ALG-000184 can become the new standard-of-care for chronic suppression of hepatitis B virus, while also serving as the oral backbone to future functional cure regimens.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$70
2025-03-31
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$70
2025-03-31
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Maintains
$75 → $70
2025-03-11
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$75 → $70
2025-03-11
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$75
2024-11-07
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$75
2024-11-07
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$75
2024-10-23
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$75
2024-10-23
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$75
2024-09-20
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$75
2024-09-20
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Aligos Therapeutics Inc (ALGS.O) is -1.37, compared to its 5-year average forward P/E of -3.24. For a more detailed relative valuation and DCF analysis to assess Aligos Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.24
Current PE
-1.37
Overvalued PE
0.63
Undervalued PE
-7.10
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.36
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.47
Undervalued EV/EBITDA
-12.19
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
63.54
Current PS
41.82
Overvalued PS
226.27
Undervalued PS
-99.20
Financials
Annual
Quarterly
FY2025Q2
YoY :
-9.05%
965.00K
Total Revenue
FY2025Q2
YoY :
-29.71%
-18.57M
Operating Profit
FY2025Q2
YoY :
-413.44%
-15.86M
Net Income after Tax
FY2025Q2
YoY :
-288.89%
-1.53
EPS - Diluted
FY2025Q2
YoY :
-19.93%
-15.61M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+120.99%
-2.37K
FCF Margin - %
FY2025Q2
YoY :
-444.62%
-1.64K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 162.3% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
298.7K
Volume
2
6-9
Months
100.5K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
200.0K
Volume
Months
6-9
1
76.3K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ALGS News & Events
Events Timeline
2025-08-20 (ET)
2025-08-20
08:41:53
Aligos Therapeutics names Ramon Polo as leader of global regulatory affairs
2025-08-13 (ET)
2025-08-13
08:35:32
Aligos Therapeutics announces first subject dosed in Phase 2 B-SUPREME study
2025-06-18 (ET)
2025-06-18
08:04:53
Aligos Therapeutics appoints Kieron Wesson as VP, head of CMC
Sign Up For More Events
Sign Up For More Events
News
5.0
08-20NewsfilterAligos Therapeutics Enhances Executive Team by Appointing Ramón Polo as Senior Vice President and Head of Global Regulatory Affairs
5.0
07-11NewsfilterAligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5.0
06-18NewsfilterAligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)
Sign Up For More News
People Also Watch
NTIC
Northern Technologies International Corp
7.400
USD
+0.34%
SENEB
Seneca Foods Corp
114.140
USD
+0.30%
VERI
Veritone Inc
3.050
USD
+6.27%
ZENV
Zenvia Inc
1.585
USD
+2.26%
LPSN
LivePerson Inc
0.932
USD
-1.27%
VOXR
Vox Royalty Corp
3.680
USD
+5.44%
BSET
Bassett Furniture Industries Inc
16.820
USD
+0.27%
QRHC
Quest Resource Holding Corp
1.865
USD
+1.36%
EBMT
Eagle Bancorp Montana Inc
17.530
USD
+0.06%
FAQ
What is Aligos Therapeutics Inc (ALGS) stock price today?
The current price of ALGS is 10.55 USD — it has decreased -4.61 % in the last trading day.
What is Aligos Therapeutics Inc (ALGS)'s business?
What is the price predicton of ALGS Stock?
What is Aligos Therapeutics Inc (ALGS)'s revenue for the last quarter?
What is Aligos Therapeutics Inc (ALGS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Aligos Therapeutics Inc (ALGS)'s fundamentals?
How many employees does Aligos Therapeutics Inc (ALGS). have?